N-acetylcysteine boosts brain and blood glutathione in gaucher and Parkinson diseases

Clinical Neuropharmacology

Volumn 36, Issue 4, 2013, Pages 103-106

  Holmay, Mary J ^a   Terpstra, Melissa ^b   Coles, Lisa D ^a   Mishra, Usha ^a   Ahlskog, Matthew ^c   Öz, Gülin ^b   Cloyd, James C ^a   Tuite, Paul J ^c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Glutathione; Magnetic resonance spectroscopy; N acetylcysteine; Redox ratio

Indexed keywords

ACETYLCYSTEINE; GLUTATHIONE;

ADULT; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GAUCHER DISEASE; HUMAN; MALE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARKINSON DISEASE; PRIORITY JOURNAL;

EID: 84880828603     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0b013e31829ae713     Document Type: Article

References (30)

1. Sian J, Dexter DT, Lees AJ, et al. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 1994;36: 348-355.
2. DeGanuto M, Pittis MG, Pines A, et al. Altered Intracellular Redox Status in Gaucher Disease Fibroblasts and Impairment of Adaptive Response Against Oxidative Stress. J Cell Physiol 2007;21: 223-235.
3. Roversi FM, Galdieri LC, Grego BHC, et al. Blood oxidative stress markers in Gaucher disease patients. Clinica Chimica Acta 2006;364: 316-320.
4. Beal MF. Oxidatively modified proteins in aging and disease. Free Radic Biol Med 2002;32(9): 797.
5. Vila M, Ramonet D, Perier C. Mitochondrial alterations in Parkinson's disease: new clues. J Neurochem 2008;107: 317-328.
6. McNaught KS, Jackson T, JnoBaptiste R, et al. Proteasomal dysfunction in sporadic Parkinson's disease. Neurology 2006;66(100): S37.
7. Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol 2003;53(Suppl 3): S26-S36.
8. Sidranski E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 2009;361: 1651-1661.
9. Westbroek W, Gustafson AM, Sidransky E. Exploring the link between glucocereborsidase mutations and parkinsonism. Trends Mol Med 2011;17(9): 485-493.
10. Hauser RA, Lyons KE, McClain T, et al. Randomized. double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease. Movement Disorders 2009;24(7): 979-983.
11. Dringen R. Metabolism and functions of glutathione in brain. Prog Neurobiol 2000;62(6): 649-671.
12. Aoyama K, Watabe M, Nakaki T. Regulation of glutathione synthesis. J Pharmacol Sci 2008;108: 227-238.
13. Aoyama K, et al. Neuronal glutathione deficiency and age-dependent neurodegeneration in the EAAC1 deficient mouse. Nat Neurosci 2006;9(1): 119-126.
14. Whillier S, Raftos JE, Chapman B, et al. Role of N-acetylcysteine in glutathione synthesis in human erythrocytes. Redox Report 2009;14(3): 115-124.
15. Berman AE, Chan WY, Brennan AM, et al. N-acetylcysteine prevents loss of dopaminergic neurons in the EAAC1-1- mouse. Ann Neurol 2011;69: 509-520.
16. Sandhir R, Sood A, Mehrotra A, et al. N-acetylcysteiene reverses mitochondrial dysfunctions and behavioral abnormalities in 3-nitroproprionic ace-induced Huntington's disease. Neurodegenerative Dis 2012;9: 145-157
17. Adair JC, Knoefel JE, Morgan N. Controlled trial of N-acetylcysteine for patients with probable Alzheimer's disease. Neurology 2001;57: 1515-1517.
18. Tkáč I, Öz G, Adriany G, et al. In vivo 1H NMR spectroscopy of the human brain at high magnetic fields: metabolite quantification at 4T vs. 7T. Magn Reson Med 2009;62(4): 868-879.
19. Gruetter R, Tkáč I. Field mapping without reference scan using asymmetric echo-planar techniques. Magn Reson Med 2000;43(2): 319-323.
20. Öz G, Tkáč I. Short-echo, single-shot, full-intensity proton magnetic resonance spectroscopy for neurochemical profiling at 4 T: validation in the cerebellum and brainstem. Magn Reson Med 2011;65(4): 901-910.
21. Provencher SW. Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed 2001;14(4): 260-264.
22. Govindaraju V, Young K, Maudsley AA. Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed 2000; 13(3): 129-153.
23. Tkáč I. Refinement of simulated basis set for LCModel analysis. Proceedings 16th Scientific Meeting, International Society for Magnetic Resonance in Medicine. Toronto: 2008: 1624.
24. Behar KL, Rothman DL, Spencer DD, et al. Analysis of macromolecule resonances in 1H NMR spectra of human brain. Magn Reson Med 1994;32(3): 294-302.
25. Provencher SW. LCModel & LCMgui user's manual. 2001.
26. Sabatini U, Celsis P, Viallard G, et al. Quantitative assessment of cerebral blood volume by single-photon emission computed tomography. Stroke 1991;22(3): 324-330.
27. Emir UE, Tuite PJ, Öz G. Elevated pontine and putamenal GABA levels in mild-moderate Parkinson disease detected by 7 Tesla proton MRS. Plos One 2012;7(1): 1-8.
28. Öz G, Terpstra M, Tkáč I, et al. Proton MRS of the unilateral substantia nigra in the human brain at 4 Tesla: detection of high GABA concentrations. Magn Reson Med 2006;55(2): 296-301.
29. Grant JE, Odlaug BL, Kim SW. N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2009;66(7): 756-763.
30. Hurd RW, Wilder BJ, Helveston WR, et al. Treatment of four siblings with progressive myoclonus epilepsy of the Unverricht-Lundborg type with N-acetylcysteine. Neurology 1996;47: 1264-1268.